ReviewHuman vaccines & immunotherapeutics2025
Evolution of the PRNT: Merging tradition and innovation to set the gold standard in the era of automation.
Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development of attenuated and inactivated Dengue strains using advanced gene editing tools.Molecular biology reports · 2026Review
- Dual role of Japanese encephalitis virus fusion loop peptide antibodies in Zika virus infection.PLoS neglected tropical diseases · 2026Article
- Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling.Pathogens (Basel, Switzerland) · 2025Article
- Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plaque reduction neutralization test (PRNT) is the gold standard for quantifying neutralizing antibodies owing to its high sensitivity and specificity. Widely used in seroepidemiological studies and vaccine development, PRNT is limited by labor-intensive procedures, reliance on highly skilled staff, and susceptibility to human bias during manual plaque counting. These limitations hinder reproducibility, throughput, and cross-laboratory standardization. This review summarizes recent efforts to automate PRNT workflows to address these issues. However, automation adoption is often constrained by high costs and the need for regulatory frameworks to ensure data integrity. Advancements in tailored hardware and software to diverse laboratory contexts are essential to maintaining PRNT's role in immunological assessments, bridging seroneutralizing methodologies with modern automation, and making automated methods more accessible. This review outlines the key requirements for PRNT's continued evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.